Drugs / ZYNRELEF
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Zynrelef | — | 2023-10-05 | europa.eu ↗ |
| Approved | EU (EMA) | Zynrelef | — | 2020-09-24 | europa.eu ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07280195 Comparator | Feb → Dec 2026 expected | — | Washington University School of Medicine | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZYNRELEF | “The purpose of this study is to determine if local intra-operative application of ZYNRELEF (topical medication) during shoulder replacement surgery improves pain control” NCT07280195 ↗ |
| Route | Topical | “ZYNRELEF (topical medication)” NCT07280195 ↗ |